Latest Breaking News On - Marion bougeard - Page 1 : comparemela.com

MIL-OSI: Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis

MIL-OSI: Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
foreignaffairs.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from foreignaffairs.co.nz Daily Mail and Mail on Sunday newspapers.

United statesFrance generalMarion bougeardRoberto iaconeAssia mouhoutJeito capitalleadsaPureos bioventuresJeito capitalamplifiesitsUniversity of strasbourgNovo holdingsFrench national institute of health insermCompany phaseSeries cfinancingAlentis therapeuticsJeito capitalPrivate equity

Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis

Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1

United statesFrance generalRoberto iaconeAlentis therapeuticstoJeito capitalamplifiesPureos bioventuresAssia mouhoutMarion bougeardFrench national institute of health insermNovo holdingsCompany phaseUniversity of strasbourgJeito capitalAlentis therapeuticsPrivate equityThomas baumert

Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders

Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating

United statesFrance generalDennis riedlAssia mouhoutNoema pharmaJeito capitaladdedJeito capitalaimsRachel mearsMarion bougeardNoema pharma the companyJeito capitalSofinnova partnersPolaris partnersGilde healthcareTuberous sclerosis complexTrigeminal neuralgia

Investegate |Jeito Capital Announcements | Jeito Capital: Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing

Investegate announcements from Jeito Capital, Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing

United statesFrance generalUnited kingdomAssia mouhoutDaniel burgessSabine dandiguianAsahi kasei pharmaMarion bougeardSv health investorsCystic fibrosis foundationJjdc incIp groupLongwood fundPulmocide ltdJeito capitalPictet alternative advisors

Investegate |Jeito Capital Announcements | Jeito Capital: Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics

Investegate announcements from Jeito Capital, Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics

United statesFrance generalNoord hollandCarsten linnemannAssia mouhoutRachel mearsArie belldegrunSanta monicaMarion bougeardKite pharma incAllogene therapeutics incNeogene therapeutics incLoncode instituteNetherlands cancer instituteJeito capitalNeogene therapeutics